1,792
Views
40
CrossRef citations to date
0
Altmetric
Original Articles

Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients

A prospective study in 24 patients followed for 2 years

, , , , , & show all
Pages 415-425 | Received 01 Sep 2014, Accepted 08 Feb 2015, Published online: 26 Mar 2015

  • Agholme F, Aspenberg P. Wnt signaling and orthopedics, an overview. Acta Orthop 2011; 82 (2): 125–30.
  • Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 2010; 25 (11): 2412–8.
  • Agholme F, Isaksson H, Kuhstoss S, Aspenberg P. The effects of Dickkopf-1 antibody on metaphyseal bone and implant fixation under different loading conditions. Bone 2011a; 48 (5): 988–96.
  • Agholme F, Macias B, Hamang M, Lucchesi J, Adrian MD, Kuhstoss S, et al. Efficacy of a sclerostin antibody compared to a low dose of PTH on metaphyseal bone healing. J Orthop Res 2014; 32 (3): 471–6.
  • Arasu A, Cawthon PM, Lui LY, Do TP, Arora PS, Cauley JA, et al. Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab 2012; 97 (6): 2027–32.
  • Bellido T. Osteocyte-driven bone remodeling. Calcif Tissue Int 2014; 94 (1): 25–34.
  • Bjerre M. Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications. Springerplus 2013; 2: 658.
  • Chantelau EA, Grutzner G. Is the Eichenholtz classification still valid for the diabetic Charcot foot? Swiss Med Wkly 2014; 144: w13948.
  • Chantelau E, Richter A, Ghassem-Zadeh N, Poll LW. “Silent” bone stress injuries in the feet of diabetic patients with polyneuropathy: a report on 12 cases. Arch Orthop Trauma Surg 2007; 127 (3): 171–7.
  • Daoussis D, Andonopoulos AP. The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling? Semin Arthritis Rheum 2011; 41 (2): 170–7.
  • Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007; 13 (2): 156–63.
  • Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 2010; 95 (5): 2248–53?.
  • Gaudio A, Privitera F, Battaglia K, Torrisi V, Sidoti MH, Pulvirenti I, et al. Sclerostin levels associated with inhibition of the Wnt/beta-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012; 97 (10): 3744–50.
  • Gaudio A, Privitera F, Pulvirenti I, Canzonieri E, Rapisarda R, Fiore CE. The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus. Diab Vasc Dis Res 2014; 11 (1): 48–52.
  • Gouveri E, Papanas N. Charcot osteoarthropathy in diabetes: A brief review with an emphasis on clinical practice. World J Diabetes 2011; 2 (5): 59–65.
  • Jeffcoate W. The causes of the Charcot syndrome. Clin Podiatr Med Surg 2008; 25 (1): 29–42, vi.
  • Kim JH, Liu X, Wang J, Chen X, Zhang H, Kim SH, et al. Wnt signaling in bone formation and its therapeutic potential for bone diseases. Ther Adv Musculoskelet Dis 2013; 5 (1): 13–31.
  • Klejna K, Naumnik B, Gasowska K, Mysliwiec M. OPG/RANK/RANKL signaling system and its significance in nephrology. Folia Histochem Cytobiol 2009; 47 (2): 199–206.
  • Kohli SS, Kohli VS. Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications. Indian J Endocrinol Metab 2011; 15 (3): 175–81.
  • Komatsu DE, Mary MN, Schroeder RJ, Robling AG, Turner CH, Warden SJ. Modulation of Wnt signaling influences fracture repair. J Orthop Res 2010; 28 (7): 928–36.
  • Laine CM, Joeng KS, Campeau PM, Kiviranta R, Tarkkonen K, Grover M, et al. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N Engl J Med 2013; 368 (19): 1809–16.
  • Li X, Grisanti M, Fan W, Asuncion FJ, Tan HL, Dwyer D, et al. Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J Bone Miner Res 2011; 26 (11): 2610–21.
  • Mabilleau G, Petrova NL, Edmonds ME, Sabokbar A. Increased osteoclastic activity in acute Charcot’s osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia 2008; 51 (6): 1035–40.
  • Macias BR, Aspenberg P, Agholme F. Paradoxical Sost gene expression response to mechanical unloading in metaphyseal bone. Bone 2013; 53 (2): 515–9.
  • Mascarenhas JV, Jude EB. Pathogenesis and medical management of diabetic charcot neuroarthropathy. Med Clin North Am 2013; 97 (5): 857–72.
  • Ndip A, Williams A, Jude EB, Serracino-Inglott F, Richardson S, Smyth JV, et al. The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy. Diabetes 2011; 60 (8): 2187–96.
  • Nybo M, Poulsen MK, Grauslund J, Henriksen JE, Rasmussen LM. Plasma osteoprotegerin concentrations in peripheral sensory neuropathy in Type 1 and Type 2 diabetic patients. Diabet Med 2010; 27 (3): 289–94.
  • Papanas N, Maltezos E. Etiology, pathophysiology and classifications of the diabetic Charcot foot. Diabet Foot Ankle 2013; 4.
  • Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005; 90 (11): 6323–31.
  • Samuelsson P, Blohme G, Fowelin J, Eriksson JW. A new non-invasive method using pulse oximetry for the assessment of arterial toe pressure. Clin Physiol 1996; 16 (4): 463–7.
  • Sapir-Koren R, Livshits G. Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles? Osteoporos Int 2014; 25(12): 2685–700.
  • Sella EJ, Barrette C. Staging of Charcot neuroarthropathy along the medial column of the foot in the diabetic patient. J Foot Ankle Surg 1999; 38 (1): 34–40.
  • Stock M, Bohm C, Scholtysek C, Englbrecht M, Furnrohr BG, Klinger P, et al. Wnt inhibitory factor 1 deficiency uncouples cartilage and bone destruction in tumor necrosis factor alpha-mediated experimental arthritis. Arthritis Rheum 2013; 65 (9): 2310–22.
  • Terekeci HM, Senol MG, Top C, Sahan B, Celik S, Sayan O, et al. Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy. Exp Clin Endocrinol Diabetes 2009; 117 (3): 119–23.
  • Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D, et al. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 2012; 90 (6): 473–80.
  • . Viapiana O, Fracassi E, Troplini S, Idolazzi L, Rossini M, Adami S, et al. Sclerostin and DKK1 in primary hyperparathyroidism. Calcif Tissue Int 2013; 92 (4): 324–9.
  • Wilson C. Bone: Wnt--1-a key player in the regulation of human bone mass? Nat Rev Endocrinol 2013; 9 (7): 377.